Top

Published in:

01-06-2011 | Hepatobiliary Tumors

Medium-Sized HCC: Achieving Effective Local Tumor Control with Combined Chemoebolization and Radiofrequency Ablation

Authors: Eleni Liapi, MD, Jean-Francois H. Geschwind, MD

Published in: Annals of Surgical Oncology | Issue 6/2011

Excerpt

Hepatocellular carcinoma (HCC) is the third most important cause of cancer-related mortality worldwide.1 In the USA, there are approximately 18,000 new HCC cases every year, and HCC incidence and mortality rates continue to increase, particularly among middle-aged Black, Hispanic, and White men.1 Most patients with HCC present with underlying liver cirrhosis, and therefore any treatment should be focused on these two disease entities concomitantly. Locoregional treatment options such as transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) are minimally invasive treatment options that may individually or in combination address the pertinent issue of successful tumor targeting and preservation of liver function. …

Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–91.

Liapi E, Georgiades CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007;10:2–11.PubMedCrossRef

Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedCrossRef

Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.PubMedCrossRef

Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–7.PubMedCrossRef

Rossi S. Percutaneous radiofrequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000; 217:119–26.PubMed

Kitamoto M, Imagawa M, Yamada H, et al. Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization. AJR Am J Roentgenol. 2003;181:997–1003.PubMed

Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol. 2002;13:1225–32.PubMedCrossRef

Yamakado K, Nakatsuka A, Takaki H, et al. Subphrenic versus nonsubphrenic hepatocellular carcinoma: combined therapy with chemoembolization and radiofrequency ablation. AJR Am J Roentgenol. 2010;194:530–5.PubMedCrossRef

10.

Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–60.PubMedCrossRef

11.

Davis GL, Alter MJ, El-Serag H et al. Aging of gepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 38:513–21PubMedCrossRef

12.

Kawaoka T, Aikata H, Takaki S, et al. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2009;32:687–94.PubMedCrossRef

13.

Maeda N, Osuga K, Higashihara H et al. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-lipiodol emulsion. Cardiovasc Intervent Radiol. 2011.

14.

Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007;25:978–86.PubMedCrossRef

Title: Medium-Sized HCC: Achieving Effective Local Tumor Control with Combined Chemoebolization and Radiofrequency Ablation
Authors: Eleni Liapi, MD
Jean-Francois H. Geschwind, MD
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1679-2

At a glance: The STEP trials

Springer Medicine

Medium-Sized HCC: Achieving Effective Local Tumor Control with Combined Chemoebolization and Radiofrequency Ablation

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2011

Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer Decreases Distant Recurrence and Could Eradicate Local Recurrence

Aggressive Surgical Approach for Patients with T4 Gastric Carcinoma: Promise or Myth?

Preoperative Serum CA 19-9 Level as a Predictive Factor for Recurrence after Curative Resection in Biliary Tract Cancer

Validation of the S Classification of Sentinel Lymph Node and Microanatomic Location of Sentinel Lymph Node Metastases to Predict Additional Lymph Node Involvement and Overall Survival in Breast Cancer Patients

Defining Cure for Esophageal Cancer: Analysis of Actual 5-Year Survivors Following Esophagectomy

Contribution of Computed Tomography to Ultrasound in Predicting Lateral Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma